statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 PR Newswire NEW YORK, May 3, 2024 Conference...

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire NEW YORK...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer...

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute PAVmed Subsidiary...

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN...

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual...

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Anthony Vendetti, an analyst from Maxim Group, has initiated a new Buy rating on PAVmed (PAVM). Anthony Vendetti has given his Buy rating due to a...

Buy Rating Affirmed for PAVmed with Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target

Q4 2023 PAVmed Inc Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript March 27, 2024
PAVmed Inc. isnt one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details...

PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PAVmed (PAVM Research Report) and Simulations Plus...

Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

Volume	17,931.00
52-Wk High	$7.76
52-Wk Low	$1.60

Period	Estimated	Reported	Surprise	Result
Q1'24	-$1.67	--	--	N/A
Q4'23	-$1.63	-$1.98	-21.49%	MISSED
Q3'23	-$1.76	-$2.07	-17.22%	MISSED
Q2'23	-$2.32	-$1.81	22.22%	BEAT
Q1'23	-$2.67	-$2.45	8.06%	BEAT

PAVM PAVmed Inc

About

Feed

News

Sentiment

Earnings

Fundamentals